Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: The effectiveness and safety of the instillation of botulinum toxin A (BTX-A) remain subjects of controversy. The meta-analysis was performed to assess the efficacy and safety of a novel intravesical instillation of BTX-A for managing overactive bladder (OAB) or interstitial cystitis/bladder pain syndrome (IC/BPS).
Method: The randomized controlled trials were retrieved from PubMed, EMBASE, and the Cochrane Library databases up to 29 January 2024. The studies included in the analysis focused on the intravesical instillation of BTX-A in patients with OAB or IC/BPS. The data extraction was independently conducted by two reviewers. The random effects model was utilized for the assessment in order to compute the overall effect sizes. The heterogeneity tests and subgroup analyses were conducted.
Results: The meta-analysis and subgroup analysis did not reveal any statistically significant differences. However, the results of the meta-analysis indicated that intravesical instillation of BTX-A could reduce episodes of urgency urinary incontinence (UUI) (overall weighted mean difference [WMD] = -0.85; 95% confidence interval [CI]: -2.99 to 1.29). In subgroup analysis, an increase in void volume (VV) at 4 weeks of follow-up (WMD = -31.99; 95% CI: -70.53 to 6.54) was observed compared to that at 12 weeks (WMD = -1.73; 95% CI: -16.98 to 13.53). In contrast to the groups receiving more than 200 units of BTX-A, patients in the group receiving 200 units or fewer of BTX-A (WMD = -16.89; 95% CI: -41.14 to 7.35) exhibited a significantly greater increase in VV.
Conslusion: The intravesical instillation of BTX-A appears to be a viable administration route that may reduce UUI and VV to some extent. In terms of safety, intravesical instillation of BTX-A demonstrated a reduced risk of UTI and post-void residual compared to the placebo group.
Systematic Review Registration: https://www.crd.york.ac.uk/PROSPERO/view/CRD42024517877.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12037478 | PMC |
| http://dx.doi.org/10.3389/fphar.2025.1586845 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Mitomycin Intravesical Solution: First Approval.
Clin Drug Investig
August 2025
Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand.
Mitomycin intravesical solution (ZUSDURI), a hydrogel formulation of the DNA synthesis inhibitor mitomycin, has been developed by UroGen Pharma, Inc. for the treatment of low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC) via intravesical instillation. In June 2025, mitomycin intravesical solution was approved for the treatment of recurrent LG-IR-NMIBC in the USA.
View Article and Find Full Text PDFCharacterization of actions of the novel gabapentinoid drug mirogabalin on painful bladder hypersensitivity in rats with lipopolysaccharide-induced chronic cystitis.
Life Sci
August 2025
Division of Physiology and Anatomy, Faculty of Pharmaceutical Sciences, Tohoku Medical and Pharmaceutical University, Sendai, Japan.
Aims: Gabapentin reduces bladder pain and overactivity in lipopolysaccharide (LPS)-induced chronic cystitis in a rat model. This study evaluated the role of the spinal cord and the descending noradrenergic pathway in the effects of mirogabalin (MGB), a novel gabapentinoid drug on painful bladder hypersensitivity in this model.
Main Methods: Chronic cystitis was induced in female Sprague-Dawley rats via repeated intravesical LPS instillation.
Prevention of catheter-related bladder discomfort and agitation by intravesical lidocaine administration during awake craniotomy: a retrospective study.
J Anesth
August 2025
Department of Anesthesiology, Nagoya University Hospital, 65 Tsurumai-Cho, Showa-Ku, Nagoya, Aichi, 466-8550, Japan.
Antibody-drug conjugates for non-muscle invasive bladder cancer: current status and future development.
Curr Opin Urol
August 2025
S.H. Ho Urology Centre, Department of Surgery, The Chinese University of Hong Kong, Hong Kong; Division of Urology, Prince of Wales Hospital, Hong kong.
Purpose Of Review: Antibody-drug conjugates (ADCs) have recently emerged as a promising targeted therapeutic strategy in urothelial carcinoma, and their application in nonmuscle invasive bladder cancer (NMIBC) is an evolving frontier. This review is timely as it synthesizes recent advances in ADC development for NMIBC, addressing critical unmet needs among both Bacillus Calmette-Guérin (BCG) naïve high-risk and BCG-unresponsive patients.
Recent Findings: The literature reveals that ADCs that target HER2, Trop-2, Nectin-4 are under active investigation.
SHR-2005, an FcγR-Dependent CD40 Agonistic Antibody with Potent Antitumor Activities and Favorable Safety Profile.
Mol Cancer Ther
August 2025
Shanghai Shengdi Pharmaceutical Co., Ltd., Shanghai, China.
Activation of CD40, a pivotal component of immune oncology, could facilitate the infiltration of immune cells into the tumor microenvironment. In this investigation, we characterized SHR-2005, a second-generation CD40 agonistic mAb, as a potential candidate for cancer immune therapy. Our results showed that SHR-2005 possessed high affinity in binding to both human and rhesus CD40 and could effectively compete with CD40L for CD40 binding.
View Article and Find Full Text PDF